Sweden
· Delayed Price · Currency is SEK Moberg Pharma AB Statistics
Total Valuation
Moberg Pharma AB has a market cap or net worth of SEK 852.62 million. The enterprise value is 547.32 million.
| Market Cap | 852.62M |
| Enterprise Value | 547.32M |
Important Dates
The last earnings date was Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Moberg Pharma AB has 46.69 million shares outstanding. The number of shares has increased by 191.30% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 46.69M |
| Shares Change (YoY) | +191.30% |
| Shares Change (QoQ) | +35.14% |
| Owned by Insiders (%) | 6.65% |
| Owned by Institutions (%) | 44.84% |
| Float | 41.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 68.94 |
| PB Ratio | 0.92 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -29.99 |
| EV / Sales | 62.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.52, with a Debt / Equity ratio of 0.00.
| Current Ratio | 22.52 |
| Quick Ratio | 22.03 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -111.81 |
Financial Efficiency
Return on equity (ROE) is -2.36% and return on invested capital (ROIC) is -2.04%.
| Return on Equity (ROE) | -2.36% |
| Return on Assets (ROA) | -2.00% |
| Return on Capital (ROIC) | -2.04% |
| Revenue Per Employee | 976,000 |
| Profits Per Employee | -2.03M |
| Employee Count | 10 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +105.06% in the last 52 weeks. The beta is 0.95, so Moberg Pharma AB's price volatility has been similar to the market average.
| Beta (5Y) | 0.95 |
| 52-Week Price Change | +105.06% |
| 50-Day Moving Average | 12.53 |
| 200-Day Moving Average | 24.22 |
| Relative Strength Index (RSI) | 65.89 |
| Average Volume (20 Days) | 765,324 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Moberg Pharma AB had revenue of SEK 8.78 million and -18.25 million in losses. Loss per share was -0.55.
| Revenue | 8.78M |
| Gross Profit | 6.45M |
| Operating Income | -25.38M |
| Pretax Income | -22.01M |
| Net Income | -18.25M |
| EBITDA | -24.73M |
| EBIT | -25.38M |
| Loss Per Share | -0.55 |
Balance Sheet
The company has 308.96 million in cash and 3.67 million in debt, giving a net cash position of 305.30 million or 6.54 per share.
| Cash & Cash Equivalents | 308.96M |
| Total Debt | 3.67M |
| Net Cash | 305.30M |
| Net Cash Per Share | 6.54 |
| Equity (Book Value) | 928.70M |
| Book Value Per Share | 19.89 |
| Working Capital | 306.73M |
Cash Flow
| Operating Cash Flow | -26.99M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 73.46%, with operating and profit margins of -288.95% and -207.75%.
| Gross Margin | 73.46% |
| Operating Margin | -288.95% |
| Pretax Margin | -250.55% |
| Profit Margin | -207.75% |
| EBITDA Margin | -281.53% |
| EBIT Margin | -288.95% |
| FCF Margin | n/a |
Dividends & Yields
Moberg Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -191.30% |
| Shareholder Yield | -191.30% |
| Earnings Yield | -3.02% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on May 24, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | May 24, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Moberg Pharma AB has an Altman Z-Score of 26.64.
| Altman Z-Score | 26.64 |
| Piotroski F-Score | n/a |